Daratumumab (Darzalex) for the treatment of multiple myeloma in adults who have already had treatment
In 2018, the Institute for Quality and Efficiency in Health Care (IQWiG, Germany) looked into whether daratumumab (trade name: Darzalex) has any advantages or disadvantages compared with the current standard treatments for people with multiple myeloma. The drug manufacturer provided IQWiG with two relevant studies. Both studies included only patients who had already had at least one treatment for multiple myeloma.
In one of the studies, daratumumab was used in combination with the drugs lenalidomide and dexamethasone. Of the 569 patients who took part in the study, 286 were given daratumumab in combination with lenalidomide and dexamethasone, and 283 patients were only given lenalidomide and dexamethasone.
In the other study, daratumumab was used in combination with bortezomib and dexamethasone. Of the 498 participants, 251 were given daratumumab in combination with bortezomib and dexamethasone, and 247 patients were only given bortezomib and dexamethasone.